Book contents
- Pharmacological Treatment of Tics
- Pharmacological Treatment of Tics
- Copyright page
- Dedication
- Contents
- Introduction: The Long and Winding Road to Tourette Syndrome
- Part I Diagnosis of Tics
- Part II Pharmacotherapy of Tics
- Chapter 3 First-Generation Anti-dopaminergic Medications
- Chapter 4 Second-Generation Anti-dopaminergic Medications
- Chapter 5 Alpha-2 Adrenergic Medications
- Chapter 6 Other Tic-Suppressing Medications
- Part III Guidelines on the Pharmacotherapy of Tics
- Further reading
- Index
Chapter 5 - Alpha-2 Adrenergic Medications
from Part II - Pharmacotherapy of Tics
Published online by Cambridge University Press: 16 August 2020
Book contents
- Pharmacological Treatment of Tics
- Pharmacological Treatment of Tics
- Copyright page
- Dedication
- Contents
- Introduction: The Long and Winding Road to Tourette Syndrome
- Part I Diagnosis of Tics
- Part II Pharmacotherapy of Tics
- Chapter 3 First-Generation Anti-dopaminergic Medications
- Chapter 4 Second-Generation Anti-dopaminergic Medications
- Chapter 5 Alpha-2 Adrenergic Medications
- Chapter 6 Other Tic-Suppressing Medications
- Part III Guidelines on the Pharmacotherapy of Tics
- Further reading
- Index
Summary
The main pharmacodynamic and pharmacokinetic properties of Clonidine (Figure 5.1) are summarized in Table 5.1. Dose is 0.025 mg daily for 14 days, then increased by 0.025 mg every 14 days; usual maintenance 0.1–0.4 mg daily in two to three divided doses (maximum dose 1.2 mg daily). The main clinical indications of Clonidine in addition to tics are listed in Table 5.3. Caution is warranted when using Clonidine in patients with the conditions listed in Table 5.4.
- Type
- Chapter
- Information
- Pharmacological Treatment of Tics , pp. 88 - 98Publisher: Cambridge University PressPrint publication year: 2020